【藥品性質提示】 根據 2019 AGS Beers Criteria，本藥品為【潛在不適當用藥 (PIM)】，不建議用於老年人 (除非用於思覺失調、雙極症、或化療止吐)。

思覺失調症 Management of schizophrenia; control of tics and vocal utterances of Tourette's disorder in children and adults; severe behavioral problems in children

First Generation (Typical) Antipsychotic
Haloperidol blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones; believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis

Time to peak (I.M): 20 minutes
Duration: 2-4 weeks
Distribution: crosses placenta; enters breast milk; Vd: 8-18 L/kg; Protein binding: 90%
Metabolism: Hepatic to inactive compounds
Elimination half-life: 18 hrs

1. Patient with severe toxic CNS depression or comatose states
2. Parkinsom's disease
3. Hypersensitivity to haloperidol

C

Enters breast milk; not recommended

Extrapyramidal reaction, tachycardia, hypotension, leukopenia, maculopapular and acne form skin reactions, anorexia, constipation

IM 2-5 mg Q4-8H as needed

(Children 6-12 years) IM 1-3 mg/dose every 4-8 hrs to a maximum of 0.15 mg/kg/day